Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review

Xenofon Baraliakos, Lianne S. Gensler, Salvatore D’Angelo, Florenzo Iannone, Ennio G. Favalli, Natasha de Peyrecave, Simone E. Auteri and Roberto Caporali

Abstract:
We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), in patients with ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis (nr-axSpA) treated with biologic therapy. Searches were limited to English language manuscripts published in the 11 years prior to 9 July 2019. Randomized controlled trials, open-label extensions (OLEs) and observational studies reporting mSASSS progression in patients with AS or nr-axSpA treated with biologics were eligible for inclusion. Bias was assessed using the methodological index for nonrandomized studies (MINORS) tool. Among the 322 studies identified in the literature search, 23 (11 OLEs and 12 cohort studies) met the eligibility criteria and were selected for inclusion. Most studies reported mSASSS progression in patients with AS receiving tumor necrosis factor inhibitor (TNFi) treatment. One study reported mSASSS progression in patients with AS treated with secukinumab, an interleukin-17A inhibitor. The mean (range) MINORS score was 11.3 (7–15) for the 15 noncomparative studies and 15 (12–22) for the 8 comparative studies. Although results of the individual studies were variable, mSASSS progression in patients with AS was generally minimal and slow with long-term TNFi therapy. Moreover, odds ratios for the likelihood of mSASSS progression with/without TNFi favoured TNFi therapy in several of the cohort studies. The rate of mSASSS progression following continuous secukinumab treatment was low and remained stable over 4 years. Of two studies reporting progression in patients with nr-axSpA treated with TNFis, one showed no mSASSS progression; however, the lack of control limited comparative conclusions.

Keywords: ankylosing spondylitis, biologic therapy, interleukin-17A inhibitor, radiography, tumor necrosis factor inhibitor

Introduction
Spondyloarthritis, characterized by inflammation of the spine and peripheral joints, includes a range of diseases such as axial spondyloarthritis (axSpA), psoriatic arthritis, reactive arthritis and enteropathic arthritis.1,2 AxSpA is a chronic inflammatory disease with a heterogeneous clinical phenotype that primarily affects the sacroiliac joints and spine. It represents a spectrum of disease, including ankylosing spondylitis (AS, also known as radiographic axSpA) and nonradiographic axial spondyloarthritis (nr-axSpA).3,4 According to the 1984 modified New York criteria, definitive radiographic sacroiliitis is required for the classification of AS.5 However, it has become apparent that this occurs late in the disease course for many patients and signs of inflammation in the sacroiliac joints and spine can be...
detected much earlier using magnetic resonance imaging (MRI). Patients with nr-axSpA may also show some evidence of spinal radiographic damage although the extent of damage is less than that reported in patients with AS.6

Initial pharmacological treatment for patients with symptomatic axSpA and predominantly axial involvement consists of nonsteroidal anti-inflammatory drugs (NSAIDs), with tumor necrosis factor inhibitor (TNFi) treatment recommended as standard practice for those patients with persistently high disease activity despite NSAID treatment.7,8 Five TNFis are indicated for patients with AS: adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. A number of these agents are also approved for nr-axSpA, though this differs by country/region. In Europe, for example, all except infliximab are indicated for nr-axSpA but only certolizumab pegol is approved for nr-axSpA in the USA.9,10 In addition, interleukin (IL)-17A inhibitors are approved for the treatment of patients with AS: secukinumab in both Europe and the USA11,12 and ixekizumab in the USA;13 as yet, no efficacy data are available in patients with nr-axSpA.

Prevention of structural damage is one of the key treatment goals for patients with axSpA7 and spinal radiographic damage is shown to be an important determinant of spinal mobility and functional impairment.14,15 However, although the clinical efficacy of biologic treatment has been established in terms of reducing inflammation and disease activity and improving patients’ function,16–18 the relatively slow rate of syndesmophyte formation and limited sensitivity of conventional radiography has made it difficult to determine the impact of biologics on spinal radiographic progression.17,19 It is thought that inflammation of subchondral bone marrow leads to local repair processes and subsequent new bone formation, suggesting that early anti-inflammatory treatment may not only be able to halt inflammation but also prevent subsequent new bone formation and radiographic progression.20

A minimum follow-up period of 2 years is required to assess spinal progression on plain radiographs and, because TNFIs have proven clinical efficacy, a 2-year placebo-controlled trial would not be ethical.21 As such, several early open-label extension (OLE) studies compared spinal radiographic progression during TNFi treatment (infliximab, etanercept and adalimumab) with progression in the historical Outcome in Ankylosing Spondylitis International Study (OASIS) cohort, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS).21–23 Several scoring methods for the measurement of radiographic progression in clinical trials of AS are available. The mSASSS has demonstrated several advantages over items such as the Bath Ankylosing Spondylitis Radiology Index (BASRI) and the unmodified SASSS,24 with changes in the mSASSS having been shown to accurately reflect deterioration in the signs and symptoms of AS, spinal mobility and physical function.25 The mSASSS can be considered the most validated and widely used tool for assessing radiographic progression in AS,26 having been endorsed by OMERACT (Outcome Measures in Rheumatology) and Assessment of SpondyloArthritis international Society (ASAS) experts as an appropriate clinical research outcome measure, given its reliability, sensitivity to change and proven feasibility for use.27

Patients in the OASIS cohort were treated according to clinical practice at the time and did not receive TNFi therapy during the 2-year follow-up period. The results of these earlier studies suggested that TNFi treatment had no effect on spinal radiographic progression at 2 years compared with standard of care; however, the studies were not designed to control for characteristics such as smoking status or baseline disease activity assessed by Ankylosing Spondylitis Disease Activity Score (ASDAS). A prospective observational study reported that TNFi treatment was associated with a 50% reduction in the odds of mSASSS progression compared with no TNFi treatment (70% after propensity score matching), with patients treated within 10 years of disease onset less likely to show progression compared with patients treated later.19 These results suggested that there may be a role for early and long-term biologic therapy in slowing down spinal radiographic progression in patients with AS. Because most studies in this area have only included patients with AS, the effect of biologic therapy on spinal radiographic progression in patients with nr-axSpA is not fully defined.

Our objective was to perform a structured literature review of spinal radiographic progression, as assessed by mSASSS, in patients with AS or nr-axSpA treated with biologic therapy.
Materials and methods

Structured literature search and study selection

‘Structured reviews’ are literature reviews that, while highly structured in approach, are not as rigorous as a full systematic review. This approach was selected over a systematic review to evaluate the research question within a relatively short timeframe, while providing a comprehensive overview of the published literature on spinal radiographic progression with biologic therapy in patients with AS/nr-axSpA. This structured review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Search strategies were based on the objective for the structured review, as outlined in the introduction. Search terms were developed by reviewing the background literature for terms related to the research question; the full search strategy is shown in Table A1. Searches were conducted in PubMed (incorporating MEDLINE), EMBASE and the Cochrane library; the final search was conducted on 9 July 2019. Searches were limited to English language manuscripts that were published in the preceding 11 years, reflecting when data about spinal radiographic progression with TNFi treatment became available. Abstracts from conferences and meetings were excluded because they do not provide sufficient information for an assessment of bias. Review articles (with the exception of systematic reviews), commentaries, letters and editorials were also excluded from the search because these publications do not provide sufficient information required to answer the research question. Randomized controlled trials (RCTs) and OLEs were eligible for inclusion, as were relevant observational studies. Citations were downloaded into the reference management software EndNote X7 (Clarivate Analytics, Philadelphia, USA) to check for duplicates; deduplication was replicated with a manual search in Microsoft Excel. Citations and abstracts were screened for inclusion in Excel according to the eligibility criteria defined using the PICOS approach (population, intervention, comparator group, outcome and study design). Per PICOS, the patient population was defined as patients with axSpA, including AS and nr-axSpA. The intervention was defined as any biologic, and the comparator as placebo, NSAIDs, other medications, usual standard of care or no comparator. The outcome was defined as spinal radiographic progression as determined by the mSASSS. The study design was limited to RCTs and their OLEs and relevant observational studies. Full manuscripts were obtained for any abstracts judged eligible for inclusion using PICOS, and their relevance assessed. Searches were screened and assessed for eligibility by one reviewer.

Data extraction and assessment

Data relating to study design, population and mSASSS results were extracted by one reviewer using a standardized extraction form. An assessment of bias for the outcome of interest was made using the methodological index for nonrandomized studies (MINORS) measure. The MINORS measure was selected because it is designed to assess the methodological quality of both noncomparative and comparative nonrandomized studies; furthermore, it is a validated instrument shown to have good reliability, internal consistency and validity. The MINORS measure comprises an eight-item checklist of methodological criteria for nonrandomized studies, with four additional criteria specifically for comparative studies. For each criterion, the study is scored as 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). The maximum possible score is 16 for noncomparative studies and 24 for comparative studies. As a statistical meta-analysis was not conducted, an overall assessment of quality across studies (such as heterogeneity or publication bias) was not performed.

The primary assessment was the reported likelihood of spinal radiographic progression by mSASSS in patients with AS or nr-axSpA treated with biologics. The results of this assessment are presented in tables and figures and narratively described.

Results

Literature search and selected studies

Among the 322 publications identified in the initial literature search, 23 met the eligibility criteria and were selected for inclusion (Figure A1). No RCTs were identified for inclusion; 11 studies were OLEs and the remaining 12 were cohort studies. A total of 20 studies looked at the effect of TNFi treatment on spinal radiographic progression; 12 of those examined the effect of multiple TNFIs or TNFIs as a class, and 8 examined the effect of specific TNFIs (certolizumab pegol and golimumab were each assessed in one study, while adalimumab, etanercept and infliximab...
were each assessed in two studies). Three publications looked at the effect of an IL-17A inhibitor, secukinumab, on spinal radiographic progression. Four studies (all cohort studies) assessed spinal radiographic progression in patients treated with TNFis compared with patients not treated with TNFis. Five studies (three OLEs and two cohort studies) compared spinal radiographic progression in patients treated with TNFis with historical cohorts of patients not treated with TNFis (the Herne, OASIS and Effects of Non-Steroidal Anti-Inflammatory Drugs on RAIdiographic Damage in Ankylosing Spondylitis [ENRADAS] cohorts). The remaining 14 studies did not include any comparator group for the mSASSS assessment, although one of these compared prior TNFi use versus no prior TNFi use in a multivariate analysis. Most studies reported mSASSS progression in patients with AS (Tables 1 and 2); only two of the 23 eligible publications reported this specifically in patients with nr-axSpA (Table 1). The mean MINORS score for the 15 noncomparative studies was 11.3 (range 7–15) out of a possible score of 16. The mean MINORS score for the eight comparative studies (seven OLE studies) was 12 (range 7–15) out of a possible score of 16. The mean MINORS score for the eight comparative studies (seven OLE studies) was 12 (range 7–15) out of a possible score of 16. The mean MINORS score for the eight comparative studies (seven OLE studies) was 12 (range 7–15) out of a possible score of 16. The mean MINORS score for the eight comparative studies (seven OLE studies) was 12 (range 7–15) out of a possible score of 16. The mean MINORS score for the eight comparative studies (seven OLE studies) was 12 (range 7–15) out of a possible score of 16. The mean MINORS score for the eight comparative studies (seven OLE studies) was 12 (range 7–15) out of a possible score of 16.

**Effect of biologics on spinal radiographic progression in patients with AS**

The studies reporting mSASSS outcomes in patients with AS were heterogeneous in terms of follow-up time and reported outcomes. Follow-up time ranged from 46 weeks to 10 years, with most studies reporting outcomes over a 2–4-year follow-up period. The majority of studies reported mSASSS at baseline and follow-up (Tables 1 and 2; Figure 1), with several studies reporting a statistic for the likelihood of progression in TNFi-treated patients compared with patients not treated with TNFis (Table 2).

**Tumor necrosis factor inhibitors.** The following studies are grouped according to design (OLE and cohort studies). Within each group, studies are reported chronologically, with the earlier studies presented first (Tables 1 and 2; Figure 1).

**OLE studies.** Three OLEs (1.8–2 years’ follow-up) showed no significant difference in mSASSS progression between patients treated with TNFis (adalimumab, etanercept and infliximab) and the OASIS historical cohort of TNFi-untreated patients. In the OLE of infliximab, 80.1% of patients had not progressed at 2 years (<2-point increase in mSASSS) compared with 82.4% of patients in the OASIS cohort. None of these three studies scored highly on the MINORS measure (Table 1). One short-term OLE study reported minimal mSASSS progression after 60 weeks of etanercept treatment. In an OLE of the GO-RAISE golimumab study, 4-year mSASSS progression was low [mean ± standard deviation (SD): 50 mg, 1.3 ± 4.1; 100 mg, 2.0 ± 5.6]. The rate of mSASSS progression remained stable at years 2 and 4, and, after 2 years, 73.9% of patients randomized to golimumab 50 mg had not progressed (<2-point increase in mSASSS). An analysis of two long-term OLE studies of patients treated with infliximab or etanercept showed continuous slow mSASSS progression (about 1.2 mSASSS points every 2 years) over time; however, this study scored lowest on the MINORS tool (7/16), indicating poor methodological quality. More recently, an OLE of the RAPID-axSpA study of certolizumab pegol demonstrated minimal mSASSS progression after 4 years, with a mean mSASSS change in patients with AS of 0.98 [95% confidence interval (CI) 0.34, 1.63]. The majority of progression was observed during the first 2 years of certolizumab pegol treatment (0.67), with a decrease in progression observed between years 2 and 4 (0.31; Table 1; Figure 1); at week 204, 80.6% of patients had not progressed (<2-point increase in mSASSS). Most recently, a 5-year study of 33 patients receiving TNFis (22 infliximab, 5 etanercept and 6 adalimumab) showed mSASSS progression (≥1 unit) in 19 patients, with 14 not progressing.

**Cohort studies.** In a 46-week cohort study of patients treated with TNFis, the rate of mSASSS progression was 0.94 ± 1.98 (mean ± SD). In a study comparing radiographic progression in infliximab-treated patients versus the historical Herne cohort who had not previously received TNFis, the rate of mSASSS progression over 8 years was 0.9 ± 0.8 (mean ± SD) per year and 1.5 ± 1.4 per year, respectively; however, this study had a mean mSASSS progression after 2 years (<2-point increase in mSASSS). No benefit of TNFi treatment was found in one cohort study: there was no significant difference in mSASSS change from baseline after a mean 5-year follow-up period in
Table 1. Studies of spinal radiographic progression over time in patients with AS or nr-axSpA treated with biologic therapies.

| Study                          | Design | Therapy     | mSASSS comparator | Duration of follow-up | N* | Baseline mSASSS | Reported mSASSS outcomes | Observed or modeled data* | MINORS score |
|--------------------------------|--------|-------------|-------------------|-----------------------|-----|----------------|-------------------------|---------------------------|---------------|
| van der Heijde et al. 2008†⁵   | OLE    | Etanercept‡ | Historical control [OASIS cohort] | 96 weeks             | 432 | - Etanercept [n=257], 16 ± 18.3 - OASIS [n=175], 14 ± 17.6 - OASIS matched* [n=76], 19 ± 20.8 | mSASSS change from baseline at 96 wks - Etanercept, 0.91 ± 2.45 - OASIS 0.95 ± 3.18 - OASIS matched* 1.27 ± 3.64 p=1.0 for etanercept vs OASIS p=NS for etanercept vs OASIS matched* | Observed, adjusted, missing values imputed | 12/24         |
| ASSERT van der Heijde et al. 2008‡¹² | OLE    | Infliximab  | Historical control [OASIS cohort] | 2 years              | 393 | - ASSERT cohort [n=190], 17.7 ± 17.9 - OASIS [n=176], 15.8 ± 18.1 - OASIS matched* [n=65], 17.5 ± 19.1 | mSASSS change from baseline - ASSERT [n=156], 0.9 ± 2.6 - OASIS [n=165], 1.0 ± 3.2 - OASIS matched* [n=61], 1.2 ± 3.9 p=0.541 for ASSERT vs OASIS p=0.683 for ASSERT vs OASIS matched* | Observed, adjusted | 16/24         |
| ATLAS, M03-606 (pooled analysis) van der Heijde et al. 2009†³⁵ | OLE    | Adalimumab† | Historical control [OASIS cohort] | 2 years             | 476 | - Adalimumab [n=307], 19.8 ± 19.3 - OASIS cohort [n=169], 15.8 ± 17.6; p=0.028 | mSASSS change from baseline to 2 years - Adalimumab, 0.8 [2.6] - OASIS, 0.9 ± 3.3 - OASIS matched [n=77], 0.9 ± 4.1 p=0.771 for adalimumab vs OASIS p=0.744 for adalimumab vs OASIS matched* | Observed, adjusted | 14/24         |
| Dijkmans et al. 2009¹³         | OLE    | Etanercept† | None              | 60 weeks            | 67  | - Placebo crossover [n=34], 11.95 ± 16.8 - Etanercept only [n=33], 18.27 ± 21 | mSASSS at wk 60 - Placebo crossover, 11.79 ± 16.8 - Etanercept only, 18.63 ± 20.9 | Observed | 12/16         |
| GO RAISE Braun et al. 2014†⁴⁴  | OLE    | Golimumab‡ | None              | 208 weeks           | 299 | - Placebo [n=66], 16.1 ± 18.7 - Golimumab 50 mg [n=111], 11.7 ± 16.4 - Golimumab 100 mg [n=122], 13.5 ± 18.9 | mSASSS change from baseline to wk 104: - Placebo crossover, 1.6 ± 4.6 - Golimumab 50 mg, 0.9 ± 2.7 - Golimumab 100 mg, 0.9 ± 3.9 | Observed | 11/16         |

(Continued)
| Study | Design | Therapy | mSASSS comparator | Duration of follow-up | N* | Baseline mSASSS | Reported mSASSS outcomes* | Observed or modeled data*† | MINORS score |
|-------|--------|---------|-------------------|-----------------------|-----|----------------|---------------------------|---------------------------|--------------|
| OLE   | TNFis  | None    | 10 years          | 60                    | All, 11.1 ± 6.1 | mSASSS at follow-up   | Observed | 7/16 |
|       |        |         |                   |                       | - Placebo crossover, 71.2% | - Year 2 [n=57], 12.9 ± 17.2 |
|       |        |         |                   |                       | - Golimumab 50 mg, 73.9%  | - Year 4 [n=41], 12.0 ± 2.3 |
|       |        |         |                   |                       | - Golimumab 100 mg, 71.3% | - Year 6 [n=34], 14.6 ± 17.1 |
|       |        |         |                   |                       | Non-progressors†      | - Year 8 [n=23], 16.0 ± 17.5 |
|       |        |         |                   |                       |                         | - Year 10 [n=17], 17.2 ± 17.7 |
| OLE   | Secukinumab | None   | 104 weeks         | 168                   | - 75 mg [n=62], 10.8 ± 16.7 | mSASSS change from baseline at wk 104 | Observed | 12/16 |
|       |        |         |                   |                       | - 150 mg [n=86], 9.6 ± 16.6 | - 75 mg, 0.31 ± 3.04 |
|       |        |         |                   |                       | - Pooled dose cohort [n=168], 10.22 ± 16.62 | - 150 mg, 0.30 ± 1.94 |
|       |        |         |                   |                       | Non-progressors††    | - Pooled dose cohort, >80% |
| OLE   | Certolizumab | None   | 204 weeks         | 113                   | 13.2                      | mSASSS change from baseline§ | Modeled | 11/16 |
|       |        |         |                   |                       | Non-progressors**  | - At wk 96, 0.67 |
|       |        |         |                   |                       |                         | - At wk 204, 0.98 |
|       |        |         |                   |                       |                         | - Years 0–2, 0.67 [95% CI 0.21, 1.13] |
|       |        |         |                   |                       |                         | - Years 2–4, 0.31 [95% CI 0.02, 0.60] |
| OLE   | Secukinumab | None    | 4 years           | 155                   | 150 mg [n=71], 8.6  | mSASSS change from baseline at wk 208 | Observed | 13/16 |
|       |        |         |                   |                       | 75 mg not uptitrated [n=61], 8.5 | - 150 mg 9.9; Δ1.2 ± 3.91 |
|       |        |         |                   |                       | 75 mg uptitrated [n=23], 15.7 | - 75 mg not uptitrated 10.3; Δ1.8 ± 4.32 |
|       |        |         |                   |                       | Non-progressors: | - 75 mg uptitrated 17.3; Δ1.6 ± 5.67 |
|       |        |         |                   |                       | 75 mg: 78.6%, 150 mg: 78.9% |
| OLE   | TNFis  | None    | 5 years           | 33                    | 10.5 ± 12.5              | 15.5 ± 13.9 | 42.4% | Observed | 15/16 |
|       |        |         |                   |                       | Non-progressors**  |
| Cohort studies in AS | | | | | | | | | |
| OLE   | TNFis  | None    | 46 weeks          | 36                    | Median: 13 [IQR 6, 24] | mSASSS at wk 46 | Observed | 10/16 |
|       |        |         |                   |                       | - Median 15 [IQR 6, 24] | p=0.005 for wk 46 vs baseline |
| Study                | Design   | Therapy | mSASSS comparator | Duration of follow-up | N*  | Baseline mSASSS# | Reported mSASSS outcomes# | Observed or modeled data | MINORS score |
|---------------------|----------|---------|-------------------|-----------------------|-----|-----------------|---------------------------|--------------------------|-------------|
| Haroon et al. 2013  | Cohort   | TNFi    | TNFi untreated patients | 2.9 ± 1.03 years | 334| TNFi 10.6 ± 14.9 [n=201] | Prior anti-TNF vs no TNFi: OR 0.52 [95% CI 0.30, 0.88]; p=0.02 | Observed                | 18/24       |
| Baraliakos et al. 2014 | Cohort   | TNFi    | DIKAS cohort, Herne cohort | 8 years | 56 | DIKAS cohort [n=22], 13.2 ± 17.6 | DIKAS cohort 20.2 ± 21.4, Herne cohort 25.9 ± 17.8 p=0.047 for comparison between cohorts | Modeled, adjusted       | 12/24       |
| Kim et al. 2016     | Cohort   | TNFi    | TNFi untreated patients | Mean 5.01 ± 1.24 years | 610| TNFi treated: Mean 5.01 ± 1.24 years | mSASSS at follow-up: DIKAS cohort, 20.2 ± 21.4, Herne cohort, 25.9 ± 17.8 p=0.047 for comparison between cohorts | Observed, adjusted      | 12/24       |
| Park et al. 2016    | Cohort   | TNFi    | None              | Mean 5.09 ± 1.07 years | 165| 13.5 ± 16.6 | Rate of mSASSS progression: DIKAS cohort, 0.9 ± 0.8 per year, Herne cohort, 1.5 ± 1.4 per year p=0.129 | Modeled                  | 14/16       |
| Maas et al. 2017    | Cohort   | TNFi    | None              | 6 years | 80 | 8.7 ± 13.3 | Overall rate of mSASSS progression: 0–2 years: 1.7 [95% CI 1.1, 2.3], 2–4 years: 1.5 [95% CI 0.8, 2.3], 4–6 years: 1.0 [95% CI 0.1, 2.1] | Modeled                  | 14/16       |
| Jeong et al. 2018   | Cohort   | TNFi    | None              | Mean 102.9 ± 54.9 months | 151| 7.6 ± 10.8 | Overall rate of mSASSS progression: 1.01 ± 1.23 per year | Observed                 | 14/16       |

| Study                | Design   | Therapy | mSASSS comparator | Duration of follow-up | N*  | Baseline mSASSS# | Reported mSASSS outcomes# | Observed or modeled data | MINORS score |
|---------------------|----------|---------|-------------------|-----------------------|-----|-----------------|---------------------------|--------------------------|-------------|
| Maas et al. 2017    | Cohort   | TNFi    | None              | 8 years | 210| 10.0 ± 15.5 | mSASSS change from baseline: At 2 years [n=163], 1.6 ± 2.8, At 4 years [n=132], 3.5 ± 4.6, At 6 years [n=80], 4.2 ± 4.8, At 8 years [n=41], 7.0 ± 6.3 | Observed                | 14/16       |
| Jeong et al. 2018   | Cohort   | TNFi    | None              | Mean 102.9 ± 54.9 months | 151| 7.6 ± 10.8 | Overall rate of mSASSS progression: 1.01 ± 1.23 per year | Observed                 | 8/16        |

TNFi use >84 months after symptom onset vs within 84 months: 1.32 ± 0.16 vs 0.68 ± 0.10; p=0.001
| Study | Design | Therapy | mSASSS comparator | Duration of follow-up | N* | Baseline mSASSS | Reported mSASSS outcomes** | Observed or modeled data | MINORS score |
|-------|--------|---------|-------------------|-----------------------|-----|----------------|---------------------------|---------------------------|-------------|
| Mohur et al. 2018** | Cohort | TNFis untreated patients | 10 years | 432 | 6.6 ± 12.5 | Change from baseline over 2 years: 0.79 ± 0.11 (p=0.026) | Observed | 10/16 | 23 |
| Park et al. 2019 | Cohort | TNFis (SCQM cohort) | 10 years | 432 | 6.6 ± 12.5 | Change from baseline over 2 years: 0.79 ± 0.11 (p=0.026) | Observed | 10/16 | 23 |
| Beek et al. 2019** | Cohort | TNFis None | Mean 4.5 years | 135 | 1.6-27.2 | Change from baseline over 2 years: 0.79 ± 0.11 (p=0.026) | Observed | 10/16 | 23 |
| Braun et al. 2019a | Cohort | TNFis IEnRADAS cohort | 2 years | 237 | Mean ± SD | Change from baseline over 2 years: 0.79 ± 0.11 (p=0.026) | Observed | 10/16 | 23 |
| Möller et al. 2019 | Cohort | TNFis (ENRADAS cohort) | Mean 4.5 years | 135 | 1.6-27.2 | Change from baseline over 2 years: 0.79 ± 0.11 (p=0.026) | Observed | 10/16 | 23 |
| Canterini et al. 2015** | Cohort | TNFis None | Mean 23.7 range | 37 | 0.625 ± 0.518 | Change from baseline over 2 years: 0.79 ± 0.11 (p=0.026) | Observed | 10/16 | 23 |
| RAPID-axSpA | OLE | Certolizumab pegol | None | 83 | 4,422 | Change from baseline over 2 years: 0.79 ± 0.11 (p=0.026) | Observed | 10/16 | 23 |

**For mSASSS assessment, Meunier et al. 2016, standard deviation unless otherwise specified. †Refers to whether outcomes were based on observed data only or estimated using statistical modelling of observed data. ††Progression defined as ≥2 point increase in mSASSS. †††Refers to whether outcomes were based on observed data only or estimated using statistical modelling of observed data. ωProgression defined as ≥2 point increase in mSASSS. **Change from baseline over 2 years. Modelled.
### Table 2. Relationship between TNFi treatment and spinal radiographic progression in patients with AS.

| Study            | Design     | Therapy | Length of follow-up | N* | Baseline mSASSS# | Likelihood of progression                                                                 | Type of analysis                                                                 | MINORS score |
|------------------|------------|---------|---------------------|----|------------------|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------|
| Haroon et al. 2013¹³ | Cohort     | TNFis   | TNFi treated        | 334| All, 9.6 ± 14.5   | TNFi treatment vs no TNFi treatment, OR 0.52 (95% CI 0.30, 0.88); p=0.02                | Univariate, adjusted for baseline mSASSS**                                      | 18/24       |
|                  |            |         | - Mean 2.9 ± 1.03 years |    | - TNFi treated |                                             |                                                                                  |              |
|                  |            |         | TNFi untreated      |    | 10.6 ± 14.9      | TNFi treatment vs no TNFi treatment in 142 post-propensity score matched samples, OR 0.30 (95% CI 0.11, 0.78); p=0.01 | Multivariate, adjusted†                                                           |              |
|                  |            |         | - Mean 2.8 ± 1.1 years |    | - TNFi untreated| TNFi treatment for >50% of disease duration vs <50%, OR 0.2 (95% CI 0.04, 0.92); p=0.04 | Univariate, adjusted for baseline mSASSS**                                      |              |
|                  |            |         |                     |    | 8.2 ± 13.8       | Delay in starting therapy of >10 years vs ≤ 10 years, OR 2.4 (95% CI 1.09, 5.3); p=0.03   | Univariate, adjusted for baseline mSASSS**                                      |              |
| Kim et al. 2016⁰¹ | Cohort     | TNFis   | TNFi treated        | 610| 18.87 ± 17.96    | TNFi treatment vs no TNFi treatment, OR 0.79 (95% CI 0.56, 1.11); p=0.17                 | Univariate                                                                        | 12/24       |
|                  | (OSKAR cohort) |        | - Mean 5.01 ± 1.24 years |    | - TNFi treated | TNFi treatment vs no TNFi treatment in 166 post-propensity score matched samples, OR 0.69 (95% CI 0.29, 1.63); p=0.41 | Multivariate, adjusted for disease duration, baseline mSASSS and TNFi exposure |              |
|                  |            |         | TNFi untreated      |    | 15.68 ± 15.49    | TNFi treatment vs no TNFi treatment in 166 vs 166 post-propensity score matched samples, OR 0.69 (95% CI 0.29, 1.63); p=0.41 | Multivariate, adjusted for disease duration, baseline mSASSS and TNFi exposure |              |
|                  |            |         | - Mean 5.09 ± 1.07 years |    | - TNFi untreated| TNFi treatment vs no TNFi treatment, OR 0.79 (95% CI 0.56, 1.11); p=0.17                 | Multivariate, adjusted for disease duration, baseline mSASSS and TNFi exposure |              |
| Jeong et al. 2018⁰³ | Cohort     | TNFis   | Mean 102.9 ± 54.9 months | 151| 7.6 ± 10.8       | Time to start TNFi, β-coefficient 0.004 [SE 0.001]; p=0.001                              | Univariate                                                                  | 8/16        |
|                  |            |         |                     |    |                  | Time to start TNFi, β-coefficient -0.007 [SE 0.004]; p=0.077                      | Multivariate, adjusted for time to start TNFi                                     |              |
|                  |            |         |                     |    |                  | Time to start TNFi, β-coefficient -0.008 [SE 0.004]; p=0.048                      | Multivariate, adjusted for TNFi index§                                          |              |
| Molnar et al. 2018⁰⁴ | Cohort     | TNFis   | Up to 10 years      | 432| 6.6 ± 12.5       | Number of years of continuous TNFi use prior to a 2-year radiographic interval, OR 0.79 (95% CI 0.66, 0.94); p=0.01 | Multivariate, adjusted⁰                                                        | 10/16       |
|                  | (SCQM cohort) |        |                     |    |                  |                                             |                                                                                  |              |
|                  |            |         |                     |    |                  | TNFi use prior to a 2-year radiographic interval lyes vs no), OR 0.50 (95% CI 0.28, 0.88); p=0.02 | Multivariate, adjusted⁰                                                        |              |
|                  |            |         |                     |    |                  | Number of years of continuous TNFi use prior to a 2-year radiographic interval lyes vs no), OR 0.87 (95% CI 0.49, 1.56); p=0.64 | Multivariate, adjusted⁰                                                        |              |

¹For mSASSS assessment; ²Mean ± standard deviation, unless otherwise specified; ³Adjusted for multiple baseline clinical and demographic characteristics; ⁴Estimated effect of TNFi per year of continuous TNFi use; ⁵Ratio of period of TNFi use: entire period of disease; ⁶Additional multivariate analysis and analyses in matched samples are also reported but have not been included here for simplicity.

CI, confidence interval; MINORS, methodological index for non-randomized studies; mSASSS, modified Stokes Ankylosing Spondylitis Spine Score; OR, odds ratio; OSKAR, Observation Study of the Korean SpondyloArthropathy Registry; SCQM, Swiss Clinical Quality Management; SE, standard error; TNF, tumor necrosis factor.
TNFi-treated versus TNFi-untreated patients.\textsuperscript{41} The MINORS score was low, indicating poor methodological quality (12/24). In another cohort study, mSASSS progression in TNFi-treated patients with risk factors for spinal radiographic progression was found to be nonlinear, with a higher rate of progression observed over 0–2 years (maximum 2.8 across risk factors) compared with 4–6 years (minimum 0.9 across risk factors). In TNFi-treated patients without risk factors, progression was linear at a rate of $\leq 1$ per 2 years.\textsuperscript{43} After 6 years, 75% of patients had not progressed (based on the smallest detectable change). In patients followed for up to 8 years in the same study, a reduction in the rate of mSASSS progression was observed after 4 years' follow-up.\textsuperscript{44} The MINORS score was 14/16, indicating that, although nonrandomized, the study was of good methodological quality. In a long-term cohort study (mean follow-up, 102.9 months), a significantly lower rate of mSASSS progression was observed in patients treated with TNFis within 84 months of symptom onset versus $\geq 84$ months after symptom onset.\textsuperscript{45} The rate of mSASSS...

**Figure 1.** Spinal radiographic progression over time in patients with AS and nr-axSpA. The figure shows mean mSASSS progression at baseline in TNFi-treated (solid lines) and TNFi-untreated (dashed lines) patients with AS and nr-axSpA. Reasons for excluding data from this figure were: median rather than mean mSASSS data were reported [Pedersen et al.\textsuperscript{40} Beek et al.\textsuperscript{47}] or increases in mSASSS for individual populations were not reported [Molnar et al.\textsuperscript{4} Park et al.\textsuperscript{46}]. For studies that reported mSASSS change from baseline, absolute mSASSS at follow-up was calculated using the reported data. Both absolute and mean follow-up times are shown in the figure, depending on which were reported in the study. For further details on reported follow-up intervals, see Table 1.

AS, ankylosing spondylitis; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; nr-axSpA, nonradiographic axial spondyloarthritis; NSAIDs, nonsteroidal anti-inflammatory drugs; TNFi, tumor necrosis factor inhibitor.
progression was also significantly lower in patients treated with TNFis for $\geq 40.9\%$ of disease duration versus $< 40.9\%$ of disease duration. A cohort study with a 4-year follow-up period showed that there was no significant difference between rate of progression in the first 2 years of treatment [1.36 (95% CI 0.82, 1.89)] compared with the second 2 years of treatment [1.25 (95% CI 0.82, 1.68)] $p = 0.757$. This study, which compared cohorts of patients treated with a TNFi with patients treated with NSAIDs, found that radiographic progression over 2-year intervals was significantly slower with TNFIs than with NSAIDs $[\beta = -0.90 \ (95\% \ CI \ -1.51, \ -0.29) \ p = 0.004]$. However, in another study, radiographic progression in patients receiving TNFi treatment over a 4-year period showed an increase in median mSASSS of 2.5 points ($p < 0.001$). Three cohort studies reported an odds ratio for the likelihood of mSASSS progression with versus without TNFi treatment. The odds ratio reported in each of these studies favoured TNFi treatment, although one did not reach statistical significance (Table 2). Two studies reported an odds ratio after propensity score matching (a subgroup analysis of patients that could be matched one to one in the two arms based on propensity to receive TNFi); in each case, the risk of mSASSS progression with TNFi was further reduced in the post-propensity score-matched analysis compared with the overall analysis. Several studies demonstrated an association between the length of TNFi therapy or time to start TNFi therapy and risk of progression, with no effect of TNFis observed within a 2-year follow-up interval.

**IL-17A inhibitors.** Three papers reported mSASSS progression during treatment with the IL-17A inhibitor, secukinumab. All three papers reported mSASSS data from the OLE of the MEASURE-1 study over different follow-up periods or versus a historical cohort. Secukinumab was administered as a 10 mg/kg intravenous infusion at baseline and weeks 2 and 4, followed by subcutaneous injections of 150 mg or 75 mg every 4 weeks from week 8. Mean change in mSASSS after 2 years of treatment was 0.30 $\pm$ 2.53; as defined by the smallest detectable change, $> 80\%$ of patients had not progressed at follow-up. In another report after 4 years of continuous secukinumab treatment, mean ($\pm$ SD) mSASSS change from baseline to Week 208 was 1.2 $\pm$ 3.91 in patients receiving secukinumab 150 mg, indicating that the rate of mSASSS progression remained stable over 4 years of secukinumab treatment, with a numerically lower mSASSS change from baseline with secukinumab 150 mg versus 75 mg, regardless of uptitration. mSASSS progression was also reported from baseline to 2 years and from 2 years to 4 years; for secukinumab 150 mg, change from baseline to 2 years was 0.5 $\pm$ 1.69 and change from 2 years to 4 years was 0.7 $\pm$ 3.32.

mSASSS outcomes in the OLE of the MEASURE-1 study were also compared with the ENRADAS historical cohort of patients who did not receive biologics. Change in mSASSS over 2 years was numerically, but not significantly, lower in MEASURE-1 versus the ENRADAS cohort ($0.55 \pm 0.139$ versus $0.89 \pm 0.216$, $p = 0.1852$; least squares means $\pm$ standard errors). In the MEASURE-1 cohort, 82% of patients did not progress versus 73% of patients in the ENRADAS cohort. These findings were in agreement with published reports of mSASSS progression in TNFi-treated patients compared with progression in historical TNFi-untreated cohorts, with no significant differences observed between cohorts after 2 years of follow-up.

However, because MEASURE-1 did not include a comparator arm and contained relatively few patients, further studies are required to confirm if secukinumab is more effective than nonbiologic therapies in reducing the likelihood of spinal radiographic progression.

**Effect of TNFis on spinal radiographic progression in patients with nr-axSpA**

Two studies reported spinal radiographic outcomes with TNFIs specifically in patients with nr-axSpA; no studies of IL-17A inhibitors in patients with nr-axSpA were identified. In a small cohort study of adalimumab ($n = 37$), no mSASSS progression was observed over a 2-year mean follow-up period (range 6–76 months). The adalimumab study scored at the lower end of the MINORS score (8/16), indicating poor methodological quality. In an OLE of the RAPID-axSpA study of certolizumab pegol over a 4-year follow-up period, no mSASSS progression was observed in patients with nr-axSpA (Table 1). A limitation of both studies is the lack of a control cohort; therefore, further information is needed to establish whether TNFIs are more effective than nonbiologic therapy in reducing the likelihood of...
spinal radiographic progression in patients with nr-axSpA.

Discussion

Clinical symptoms of axSpA may be accompanied by identifiable radiographic damage or the presence of human leucocyte antigen B27,3,4 but diagnostic aspects for patients who lack the classical features of axSpA remain a matter of debate.50 The underlying pathology of axSpA may be linked to an abnormal immune response to biomechanical stress on bones and joints, and changes of the intestinal microbiome leading to the activation of the innate immunity, which has, in turn, been associated with gut inflammation.51 Current research is focusing on the relationship between the gut microbiome and systemic immune system, and its contribution to the induction and progression of autoimmune conditions, including axSpA.2,52,53 Genetic analysis and preclinical research have highlighted the key roles of IL-17 and TNF in axSpA pathogenesis and clinical symptomatology.51,54,55 IL-17 is known to promote osteoclastogenesis, while TNF triggers bone destruction and indirectly inhibits bone formation via suppression of the Wnt/β-catenin signalling pathway. This latter pathway regulates osteogenesis by promoting osteoblast formation and reducing osteoclastogenesis. IL-17 can therefore both promote bone formation in areas of inflammation and also, in action with TNF, bone destruction.56 These findings have resulted in the development of targeted therapies aimed at inhibiting these inflammatory cytokines. However, although the clinical efficacy of biologic treatment has been established in patients with axSpA,16–18 their impact on spinal radiographic progression has proven more difficult to establish.17,19

The duration of biologic treatment is an important factor in assessing its effect on spinal progression in axSpA. Conventional radiography can be an insensitive tool for evaluating progression with a relatively large measurement error43 and a requirement for a radiographic interval of at least 2 years.17,26,57 Hence, long-term treatment is necessary before radiographic progression can be detected using current techniques. A systematic literature review has recently been published on this topic, which supported this finding and determined that no significant difference in spinal radiographic progression was apparent between patients receiving and not receiving TNFi over the first 2 years; however, after 2 years, a potential protective effect of TNFi treatment was observed.58

Despite most studies in our structured literature review lacking a contemporary control, our results are generally in agreement with those reported in the abovementioned systematic review by Boers and colleagues.58 We found that prolonged biologic treatment appeared to minimize or stabilize spinal radiographic progression in patients with AS. Patients with AS who received long-term (≥4 years) TNFi treatment generally had less continuous spinal radiographic progression than those not treated with TNFIs. Spinal radiographic progression in patients with AS treated with secukinumab was also limited; however, this was reported in a single, unblinded short-term (2-year) study with no comparator arm, so additional controlled studies are required to confirm the outcome and to compare it with outcomes with other biologics. Patients with nr-axSpA treated with certolizumab pegol showed no spinal radiographic progression over a 4-year follow-up period. However, due to the lack of a control cohort of patients, further information is needed to establish whether TNFIs are effective in reducing spinal radiographic progression in this patient population. Unfortunately, the scarcity of robust data reflects the ethical challenges inherent in performing adequately controlled clinical trials, in which no treatment or the use of placebo is not permissible due to the availability of effective therapies. Nevertheless, the results of an observational study that evaluated data from TNFi-treated and -untreated patients over 10 years of follow-up support the reduction in spinal progression with TNFi but also indicate that a minimum duration of treatment (>2 years) was required before this can be observed and measured.6

Our finding that prolonged TNFi therapy was required before an effect on mSASSS progression in patients with AS could be observed may explain why the results of early, short-term OLE studies showed no beneficial effect of TNFIs on mSASSS progression. For example, in the cohort study reported by Haroon and coworkers, which found a significantly lower mSASSS change with TNFi versus no TNFi therapy (relative ratio 0.42, p = 0.04) for a radiographic interval >3.9 years, there was no significant difference when the radiographic interval was ≤3.9 years.19 Only one long-term AS study (5 years’ mean follow-up) did not find a positive impact of TNFi therapy on
mSASSS progression;\textsuperscript{41} this may have been related to differences in patient characteristics between this Korean cohort compared with other studies, such as a higher prevalence of peripheral arthritis and hip joint involvement.\textsuperscript{59} Previous publications have noted that variability among X-ray readings performed at different times, plus heterogeneous study designs and populations, may all contribute to confound study results and introduce bias into the subsequent inferences.\textsuperscript{55}

Only one study (MEASURE-1) was identified that examined the rate of mSASSS progression in patients with AS treated with an IL-17A inhibitor.\textsuperscript{36,38,48} Although the three analyses indicated a large proportion of patients had minimal radiographic progression (<2-point increase) over 4 years (~79%), and mSASSS increases were numerically lower than the ENRADAS cohort not receiving biologic therapy, further prospective studies are needed to confirm that the IL-17A inhibitor class is effective in reducing the likelihood of mSASSS progression.

Two eligible studies assessed mSASSS progression in patients with nr-axSpA.\textsuperscript{37,49} Although Cantarini and colleagues\textsuperscript{49} found no significant change in mSASSS in patients treated with adalimumab after a mean follow-up period of 2 years, the small sample size of the study (\(n=37\)), short follow-up and poor MINORS score make drawing wider conclusions difficult. The RAPID-axSpA study represents, to our knowledge, the longest follow-up of spinal radiographic progression (<2-point increase) over 4 years (~79%), and mSASSS increases were numerically lower than the ENRADAS cohort not receiving biologic therapy, further prospective studies are needed to confirm that the IL-17A inhibitor class is effective in reducing the likelihood of mSASSS progression.

It may be possible to overcome some of the methodological challenges identified during the analysis of these studies, namely the lengthy study durations required to observe radiographic progression and the inability to use a placebo control over long trial durations, with the use of newer, more sensitive imaging modalities, such as functional MRI, single-photon emission computed tomography (SPECT), or SPECT in combination with low-dose computed tomography.\textsuperscript{62,63} However, the use of such techniques generates new hurdles to surmount, including the standardization of protocols and cost implications.\textsuperscript{64,65} Furthermore, the radiation exposure for patients may limit the use of several of these techniques in daily practice.\textsuperscript{56} In the future, novel biomarkers involved in bone turnover, such as matrix metalloproteinase-3 and dickkopf-1, may prove to be more convenient and effective in predicting and monitoring spinal radiographic progression,\textsuperscript{67,68} but again, results need to be confirmed over long durations in large-scale trials before such techniques can be translated into daily clinical practice.

While the extended follow-up periods precluded a randomized placebo comparator, only three studies incorporated a contemporary control cohort with four studies including historical control cohorts. A limitation of nonrandomized studies is that potential confounding factors, such as smoking and concomitant NSAID exposure, may not be adequately addressed. A further limitation of the studies included in our review is that the mSASSS does not capture changes in the thoracic spine or facet joints.\textsuperscript{61} Nevertheless, the mSASSS remains the most widely used, validated score, and is considered the gold standard for assessing spinal structural progression in patients with axSpA.\textsuperscript{24,26,61} Due to the lack of studies including a randomized placebo comparator arm, and the heterogeneity of studies that addressed the objective for this review, no meta-analyses or formal synthesis of results could be performed; therefore, a structured literature review was considered to be the best approach to address our objective. Indeed, compared with a recently published systematic review,\textsuperscript{58} our structured literature review included a more comprehensive evidence base covering the effect of biologic treatment on spinal radiographic progression in patients with axSpA. The results of the current structured review were summarized in tables and narratively described, in line with previous approaches.\textsuperscript{29}

Substantial heterogeneity existed between studies in terms of design, patient populations, outcome measures, duration of follow-up, and type of data (observed or modelled; univariate or multivariate). In addition, our analysis included a large number of cohort studies with their associated
confounders and biases; despite using the MINORS measure to account for bias, this represents a key limitation of our analysis. It will be important to revisit this research question once further long-term follow-up data are available from RCTs involving radiographic outcomes. In conclusion, the results of this structured literature review indicate a variable effect of biologic therapy on spinal radiographic progression in patients with AS. Spinal radiographic progression with TNFi or IL-17A-inhibitor therapy was generally minimized or stabilized with longer duration (>2 years) of treatment. Assessment of comparative efficacy of the various biologics would be facilitated by further studies incorporating comparative control arms.

Acknowledgements
The authors would like to acknowledge Claire Snowball, MSc, of Ashfield Insight & Performance, Macclesfield, UK, an Ashfield company, part of UDG Healthcare plc, for assistance with defining the search parameters and for performing the literature searches. The authors also thank Rosalie Richards, PhD, of iMed Comms, Macclesfield, UK, an Ashfield Company, part of UDG Healthcare plc, for performing the eligibility screening, data extraction, bias assessment and providing medical writing support that was funded by UCB Pharma in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Salvatore D’Angelo, Florenzo Iannone, Ennio G. Favalli and Roberto Caporali devised the concept for the structured literature review.

Xenofon Baraliakos, Lianne S. Gensler, Salvatore D’Angelo, Florenzo Iannone, Ennio G. Favalli and Roberto Caporali provided substantial input to the design of the literature review.

Natasha de Peyrecave and Simone E. Auteri were involved in the interpretation of data and drafting of the manuscript.

All authors critically reviewed the manuscript and provided approval of the final version for submission.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the structured literature review and medical writing support work was funded by UCB Pharma.

Conflict of interest statement
Xenophon Baraliakos reports consultancy or speaker’s fees from AbbVie, BMS, Celgene, Chugai, Hexal, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz, Sanofi and UCB Pharma. Lianne S. Gensler reports grants from AbbVie, Amgen, Novartis, Pfizer and UCB Pharma, and personal fees from Galapagos, Janssen, Lilly, Novartis, Pfizer and UCB Pharma. Salvatore D’Angelo reports consultancy fees from AbbVie, BMS, Janssen, MSD, Novartis, Pfizer and UCB Pharma. Florenzo Iannone reports consultancy or speaker’s fees from AbbVie, BMS, Celgene, Janssen, MSD, Novartis, Pfizer and Roche. Ennio G. Favalli reports consultancy and lecture fees from AbbVie, MSD, Novartis, Pfizer and UCB Pharma. Natasha de Peyrecave and Simone E. Auteri are employees of UCB Pharma. Roberto Caporali reports speaker’s fees from AbbVie, BMS, Celgene, HSD, Lilly, Pfizer, Roche and UCB Pharma.

ORCID iD
Xenophon Baraliakos https://orcid.org/0000-0002-9475-9362

Supplemental material
Supplemental material for this article is available online.

References
1. Garg N, Van den Bosch F and Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol 2014; 28: 663–672.
2. Generali E, Bose T, Selmi C, et al. Nature versus nurture in the spectrum of rheumatic diseases: classification of spondyloarthritis as autoimmune or autoinflammatory. Autoimmun Rev 2018; 17: 935–941.
3. Dubash S, Mcgonagle D and Marzo-Ortega H. New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Ther Adv Chronic Dis 2018; 9: 77–87.
4. Ghosh N and Ruderman EM. Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. Arthritis Res Ther 2017; 19: 286.
5. Van der Linden S, Valkenburg HA and Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the
6. Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort. Ann Rheum Dis 2018; 77: 63–69.

7. Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76: 978–991.

8. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2016; 68: 282–298.

9. Rios Rodríguez V and Podobubny D. Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy. Ther Adv Musculoskelet Dis 2017; 9: 197–210.

10. Food and Drug Administration. Highlights of prescribing information: CIMZIA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125160s237lbl.pdf (2019, accessed 1 October 2019).

11. Food and Drug Administration. Highlights of prescribing information: COSENTYX. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf (2016, accessed 1 August 2018).

12. European Medicines Agency. Cosentyx (secukinumab) Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003729/WC500183129.pdf (2015, accessed 1 August 2018).

13. Eli Lilly and Company. Highlights of Prescribing Information Taltz® (ixekizumab). https://pl.lilly.com/us/taltz-uspi.pdf (2019, accessed 10 September 2019).

14. Wanders AJ, Landewé RB, Spoorenberg A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014; 73: 1455–1461.

15. Machado P, Landewé R, Braun J, et al. Modified stoke ankylosing spondylitis spinal score for ankylosing spondylitis. Ann Rheum Dis 2010; 69: 1465–1470.

16. Seppi A, Regal A, Van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 2017; 3: e000396.

17. Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess 2016; 20: 1–334, v–vi.

18. Wilson MJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015; CD005468.

19. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013; 65: 2645–2654.

20. Podobubny D and Sieper J. Mechanism of new bone formation in axial spondyloarthritis. Curr Rheumatol Rep 2017; 19: 55.

21. Van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324–1331.

22. Van der Heijde D, Landewé R and Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 3063–3070.

23. Van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11: R127.

24. Wanders AJ, Landewé RB, Spoorenberg A, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 2004; 50: 2622–2632.

25. Ramiro S, Van der Heijde D, Van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014; 73: 1455–1461.

26. Van der Heijde D, Braun J and Deodhar A, et al. Modified stoke ankylosing spondylitis spinal score for ankylosing spondylitis. Ann Rheum Dis 2010; 69: 1465–1470.
as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. *Rheumatology (Oxford)* 2019; 58: 388–400.

27. Van der Heijde D and Landewé R. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. *J Rheumatol* 2005; 32: 2048–2049.

28. York Health Economics Consortium. York Health Economics Consortium. https://www.yhec.co.uk/glossary/structured-review/ (2016, accessed 25 January 2019).

29. Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. *Rheumatol Int* 2016; 36: 685–695.

30. Bebb O, Smith FG, Clegg A, et al. Radiographic progression rate decreases over time on serial radiography and magnetic resonance imaging of sacroiliac joints and spine in a five-year follow-up study of patients with ankylosing spondylitis treated with tumour necrosis factor inhibitor. *Scand J Rheumatol* 2019; 48: 185–197.

31. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; 339: b2700.

32. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg* 2003; 73: 712–716.

33. Dijkmans B, Emery P, Hakala M, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. *J Rheumatol* 2009; 36: 1256–1264.

34. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. *Ann Rheum Dis* 2014; 73: 710–715.

35. Poddubnyy D, Fedorova A, Listing J, et al. Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF-α inhibitors for up to 10 years. *J Rheumatol* 2016; 43: 2142–2148.

36. Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. *Ann Rheum Dis* 2017; 76: 1070–1077.

37. Van der Heijde D, Baraliakos X, Hermann KA, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. *Ann Rheum Dis* 2018; 77: 699–705.

38. Braun J, Baraliakos X, Deodhar A, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. *Rheumatology (Oxford)* 2019; 58: 859–868.

39. Pedersen SJ, Weber U, Said-Nahal R, et al. Structural progression rate decreases over time on serial radiography and magnetic resonance imaging of sacroiliac joints and spine in a five-year follow-up study of patients with ankylosing spondylitis treated with tumour necrosis factor inhibitor. *Scand J Rheumatol* 2019; 48: 185–197.

40. Pedersen SJ, Sørensen IJ, Lambert RG, et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondyloarthritis treated with tumor necrosis factor alpha inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. *Arthritis Rheum* 2011; 63: 3789–3800.

41. Kim TJ, Shin JH, Kim S, et al. Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: observation study of Korean spondyloarthropathy registry (OSKAR) data. *Joint Bone Spine* 2016; 83: 569–572.

42. Park JW, Kwon HM, Park JK, et al. Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis. *PLoS One* 2016; 11: e0168958.

43. Maas F, Arends S, Wink FR, et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors. *PLoS One* 2017; 12: e0177231.

44. Maas F, Arends S, Brouwer E, et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. *Arthritis Care Res (Hoboken)* 2017; 69: 1011–1019.

45. Jeong H, Eun YH, Kim IY, et al. Effect of tumor necrosis factor α inhibitors on spinal radiographic progression in patients with ankylosing spondylitis. *Int J Rheum Dis* 2018; 21: 1098–1105.

46. Park JW, Kim MJ, Lee JS, et al. Impact of tumor necrosis factor inhibitor versus nonsteroidal antiinflammatory drug treatment on radiographic progression in early ankylosing spondylitis: its...
relationship to inflammation control during treatment. *Arthritis Rheumatol* 2019; 71: 82–90.

47. Beek KJ, Rusman T, Van der Weijden MAC, et al. Long-term treatment with TNF-alpha inhibitors improves bone mineral density but not vertebral fracture progression in ankylosing spondylitis. *J Bone Miner Res* 2019; 34: 1041–1048.

48. Braun J, Haibel H, De Hooge M, et al. Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. *Arthritis Res Ther* 2019; 21: 142.

49. Cantarini L, Fabbroni M, Talarico R, et al. Effectiveness of adalimumab in non-radiographic axial spondyloarthritis: evaluation of clinical and magnetic resonance imaging outcomes in a monocentric cohort. *Medicine (Baltimore)* 2015; 94: e1170.

50. Deodhar A, Miossec P and Baraliakos X. Is undifferentiated spondyloarthritis a discrete entity? A debate. *Autoimmun Rev* 2018; 17: 29–32.

51. Watad A, Bridgewood C, Russell T, et al. The early phases of ankylosing spondylitis: emerging insights from clinical and basic science. *Front Immunol* 2018; 9: 2668.

52. Chimenti MS, Perricone C, Novelli L, et al. Interaction between microbiome and host genetics in psoriatic arthritis. *Autoimmun Rev* 2018; 17: 276–283.

53. Gill T, Asquith M, Rosenbaum JT, et al. The intestinal microbiome in spondyloarthritis. *Curr Opin Rheumatol* 2015; 27: 319–325.

54. Sakkas LI and Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. *Autoimmun Rev* 2015; 14: 10–15.

55. Sarı I and Haroon N. Disease modification in axial spondyloarthritis. *Best Pract Res Clin Rheumatol* 2018; 32: 427–439.

56. García-Montoya L, Gul H and Emery P. Recent advances in ankylosing spondylitis: understanding the disease and management. *F1000Res* 2018; 7: pii: F1000 Faculty Rev-1512.

57. Baraliakos X. Imaging in axial spondyloarthritis. *Isr Med Assoc J* 2017; 19: 712–718.